Clinical Trial

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

Study acronym: RASolute 305
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with chemotherapy compared to placebo in combination with chemotherapy.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-05-26; most recent amendment 2026-07-06.
Trial Details
NCT Number NCT07621718
Lead Sponsor Revolution Medicines, Inc.
Conditions Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma
Enrollment 670 participants
Start Date 2026-05-22
Primary Completion 2028-12-30 (estimated)
Study Completion 2030-04-22 (estimated)
Updated on ClinicalTrials.gov 2026-08-03